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The growth of Toxoplasma gondii in cultured human fibroblasts was inhibited by recombinant human
gamma interferon at concentrations of 8 to 16 U/ml. The interferon was titrated by observing a total
inhibition of parasite plaque formation 7 days after infection. Inhibition of the growth of T. gondii in the
early days after infection was measured by marked reductions in the incorporation of radioactive uracil, a
precursor that can only be used by the parasites. This assay showed that when cells were pretreated with
gamma interferon for 1 day and then infected, inhibition of T. gondii growth could be readily detected 1 or 2
days after infection. When the pretreatment was omitted and parasites and gamma interferon were added at
the same time, no inhibition of parasite growth could be detected 1 day later, although it was apparent after 2
days. Cultures from which the gamma interferon had been removed by washing after a 1-day treatment
showed inhibition of T. gondii growth. Gamma interferon had no effect on the viability of extracellular
parasites, but it did inhibit the synthesis of host cell RNA and protein by ca. 50% 3 days after treatment.
This degree of inhibition is unlikely, of itself, to compromise the growth of T. gondii. Recombinant alpha
and beta interferons had no effect on the growth of T. gondii.
Interferons are currently assigned to three different class-
es (reviewed in reference 4). Alpha interferons are produced
by leukocytes in response to viral infection or to treatment
with double-stranded RNA. These same stimuli elicit beta
interferons from fibroblasts. In contrast, gamma interferons
are produced by T-lymphocytes in a general response to
lectins or in a specific response to antigens to which they
have previously been sensitized. All of these interferons are
potent inhibitors of viral growth. The role of the various
interferons in blocking the growth of Toxoplasma gondii is
unclear. Both chicken and mouse beta interferons were
observed to suppress the growth of this parasite in homolo-
gous host cells (17). However, no effect on the growth of T.
gondii was seen when mouse interferon was used to treat L-
cells (18). Some inhibition was found when rabbit interferon
was used to protect cultured rabbit cells, but it was uncertain
whether the effect could be ascribed to the interferon (18).
These experiments made use of interferon that was induced
in vivo and was probably a mixture of alpha and beta
interferons. More recently, no effect of human alpha or beta
interferons on the course of infection of human fibroblasts
with T. gondii was detected (1).
Studies of the action of unpurified gamma interferon
against T. gondii are complicated by the variety of lympho-
kines produced by lectin or specific-antigen stimulation of T-
cells. One of these lymphokines is macrophage-activating
factor (which could be identical to gamma interferon), and
activated macrophages are known to kill T. gondii (2). If
gamma interferon has an antiviral-like effect on T. gondii,
this effect must be demonstrated in cells other than macro-
phages. Several reports have suggested that lymphokines
produced by mouse spleen lymphocytes can suppress the
growth of T. gondii in mouse fibroblasts and kidney cells or
in permanent cell lines (12, 13, 20). These lymphokines were
induced by stimulating lymphocytes from toxoplasma-im-
mune animals with T. gondii antigens. The active factor
termed toxoplasma growth-inhibiting factor was observed to
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have the approximate molecular weight and lability at pH 2
and the isoelectric point expected of gamma interferon (20,
21). These studies encouraged us to examine the effect of
highly purified human recombinant gamma interferon (8).
MATERIALS AND METHODS
Our cloned line of the RH strain of T. gondii was used in
all experiments. The parasites were maintained by serial
passage in human fibroblast monolayer cultures and titrated
by plaque formation in these cultures (15). The results of
these titrations are reported in PFU. The PFU/parasite ratio
was ca. 0.5 when parasites just released from host cells by
forced passage through a 27-gauge needle were used. That is,
approximately half of these parasites were viable in the
plaque assay. The human fibroblast cells were grown in
Eagle (7) minimal essential medium that contained antibiot-
ics and 10% fetal bovine serum as previously described (15).
The serum concentration was reduced to 3% for interferon
treatment and for infection of human fibroblast cells. All
experiments with interferon were carried out with confluent
monolayer cultures in trays that contained wells of 1.6 or 2.3
cm in diameter. To prepare cultures with T. gondii plaques
for photography, the monolayers were fixed with methanol-
acetic acid-water (50:7:43, by volume) for 10 min and then
stained with 200 mg of Coomassie blue per ml in the fixation
solution.
The extent of the growth of T. gondii in monolayer
cultures was determined by measuring the incorporation of
[3H]uracil into acid-precipitable material. Wells that were to
be labeled 24 h after infection received 5 x 104 PFU,
whereas those to be labeled 48 h after infection received 8 x
103 PFU. Infected and uninfected control cultures in 24-well
trays were labeled by adding to the existing medium 50 ,ul of
medium that contained a total of 5 ,uCi. After a 2-h incuba-
tion, the radioactive medium was dumped from the well tray,
and the monolayers were washed by immersing the entire
tray in a large beaker of Hanks (9) balanced salt solution.
The monolayer was then fixed to the plastic surface by a 1-h
treatment with ice-cold 0.3 N trichloroacetic acid. The fixed
monolayers were rinsed overnight in cold running tap
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water to remove all remaining acid-soluble radioactivity.
Control experiments showed that no acid-precipitable radio-
active material was lost during this washing. The fixed
monolayers in washed and dried well trays were dissolved
by overnight treatment with 500 ,ul of 0.1 NaOH at 37°C in a
humid desiccator. The radioactivity in the NaOH solution
was measured by a water-miscible scintillation fluid that
contained sufficient acetic acid to make the mixture acidic.
Preliminary experiments showed that this method of measur-
ing the incorporation of [3H]uracil yielded the same data as
the usual filtration method but with improved convenience
and reproducibility. This method was also used to measure
the incorporation of [3H]uridine, [3H]thymidine, and
[3H]leucine into uninfected human fibroblast monolayer
cultures.
Human recombinant gamma interferon was supplied by
Genentech, Inc., at a concentration of 107 U/ml in 0.5 M
NaCl that contained 20 mM Tris-hydrochloride (pH 8.0) and
0.1% (vol/vol) beta-mercaptoethanol. We prepared a 10-fold
dilution in the same solution and stored both at 4°C. On the
day of use, a small volume of the 106-U/ml solution was
diluted to 103 U/ml in medium that contained 3% fetal bovine
serum, and this dilution was sterilized by filtration. Human
recombinant alpha and beta interferons supplied by Genen-
tech, Inc., were stored and diluted in the same way. All of
the interferon concentrations reported here are based on the
titrations carried out by Genentech, Inc., with vesicular
stomatitis virus and HeLa cells. We titrated the antiviral
activity of these interferons with the same virus but with our
human fibroblast cells, with the endpoint being the cytopath-
ic effect as determined microscopically.
[3H]uracil (20 Ci/mmol) was purchased from Moravak
Biochemicals. [5,6-3H]uridine (52 Ci/mmol), [methyl-3H]thy-
midine (6 Ci/mmol), and L-[4,5-3H]leucine (40 Ci/mmol) were
purchased from Amersham Corp.
RESULTS
One of the most common assays for the antiviral activity
of interferon is the plaque reduction test. In this type of
assay, cultures are treated with serial dilutions of interferon
for an appropriate interval and then challenged with suffi-
cient virus to yield a countable number of plaques. The
endpoint is the highest dilution of interferon that produces a
specific reduction in the number of plaques. Since T. gondii
forms plaques in human fibroblasts with high efficiency, we
began our studies of recombinant human interferons with
this assay. Figure 1 shows a typical plaque reduction assay
of recombinant gamma interferon in which the cultures were
treated for 24 h and then infected. An examination of stained
cultures 1 week after infection showed that the formation of
macroscopic plaques was totally suppressed by this interfer-
on at 8 U/ml. The MIC of the human recombinant gamma
interferon for T. gondii was measured by plaque reduction in
parallel with each experiment reported below and always fell
within the narrow range of 8 to 16 U/ml.
Although a plaque reduction assay is the definitive test for
interferon activity, the fact that the results can only be read 1
week after infection does not permit a detailed examination
of the early events that result in the inhibition of parasite
growth. We therefore turned to an assay that measured T.
gondii growth by the incorporation of [3H]uracil. We have
previously shown that this precursor is specifically incorpo-
rated by the parasites in infected cultures because they, but
not the host cells, contain the salvage enzyme uracil phos-
phoribosyltransferase (14). Uninfected cultures were also
labeled in every experiment and consistently incorporated
less than 1% of the radioactivity found in the control cultures
that were infected but not treated with interferon. To demon-
strate that the incorporation of [3H]uracil was a valid mea-
sure of T. gondii growth in interferon-treated cultures, we
titrated gamma interferon in parallel by measuring both the
incorporation of uracil and the production of viable para-
sites. For this latter assay, the intracellular parasites were
released by artificial lysis of the host cells. The dilution
required for the subsequent plaque assay reduced the inter-
feron concentration at least 10-fold below the MIC. The
assay of the interferon activity by the measurement of uracil
incorporation and of viable parasites gave concordant results
(Fig. 2).
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FIG. 1. Assay of human recombinant gamma interferon by its effect on the formation of plaques by T. gondii. Cultures were incubated in
fresh medium with various dilutions of interferon ranging from 1 to 64 U/ml as indicated. After 1 day, the cultures were infected with ca. 50
PFU and incubated for an additional 7 days before fixing and staining.
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FIG. 2. Comparison of the inhibition of T. gondii by gamma
interferon as measured by the incorporation of [3H]uracil and by the
assay of viable parasites. A series of replicate cultures was treated
with various concentrations ofgamma interferon. One day later, the
cultures were infected with 104 PFU. Three days later, the growth of
the parasites was measured by the incorporation of [3H]uracil during
a 2-h pulse and by a plaque assay of the viable parasites released
from the cells and diluted sufficiently to eliminate any effect of the
interferon. The data from each method are plotted as the percentage
of the control PFU or counts per minute observed in the absence of
interferon. Symbols: 0, average of quadruplicate radioactivity
determinations; 0, average of plaque assays from duplicate cul-
tures.
The use of [3H]uracil incorporation allowed us to measure
the kinetics of the inductiQn of an antitoxoplasma state by
gamma interferon. We measured the inhibitory effect of
gamma interferon on the growth of T. gondii during the first
2 days of infection. As is customary when antiviral activity is
measured, the interferon was added to the cultures for 1 day
before infection. We then measured uracil incorporation
both 1 and 2 days after infection. The inhibitory effect of the
gamma interferon can be observed only 1 day after infection
TABLE 1. Inhibition of the growth of T. gondii by gamma
interferon added to the human fibroblast host cells 24 h before
infection
% of control [3HIuracil incorporationa at
Interferon following time after infection:
(U/ml)
24 h 48 h
64 18 lb 3 t 0.2
32 20±3 5±0.5
16 23±4 6±1
8 78 30 27 8
a The control incorporation in the absence of interferon was 7.6 x
104 cpm per culture 24 h after infection and 4.4 x 104 cpm per
culture 48 h after infection.
b Mean and standard deviation of quadruplicate samples.
TABLE 2. Inhibition of the growth of T. gondii by gamma
interferon added at the time of infection of the human fibroblast
host cells
% of control [3Hluracil incorporationa at following
Interferon time after infection:
(U/ml)
24 h 48 h
128 91 ± 4b 12 ± 2
64 82 ± 3 9 ± 1
32 102 ± 3 11 ± 1
16 107±3 16±3
a The control incorporaiton in the absence of interferon was 1.1 x
i05 cpm per culture 24 h after infection and 7.8 x 104 cpm per
culture 48 h after infection.
b Mean and standard deviation of quadruplicate samples.
and is even more pronounced when measured after an
additional day (Table 1). These data and those presented
below are typical of many experiments in which the same
pattern was observed, although the endpoint, represented by
the MIC of gamma interferon, varied over a twofold range.
This degree of variation is common in other serological
assays. We next determined whether the inhibitory effect of
gamma interferon could be observed when the parasites
were added at the same time as the interferon. Although no
inhibition was observed 1 day after infection, the growth of
the parasites was reduced when measured 2 days after
infection (Table 2).
Since cultures treated with gamma interferon required ca.
1 day to establish a parasite-resistant state, we next deter-
mined whether it was essential that the medium contain
interferon once this resistant state was established. A series
of cultures were treated with gamma interferon for 1 day.
The medium from all cultures was then removed and saved.
The cultures were washed repeatedly with medium that
contained no interferon and then were reincubated either
with the original interferon medium or with used medium to
which interferon had not been added. The efficiency of the
washing procedure was confirmed by testing the final wash
of the cultures treated with the highest gamma interferon
concentration, 128 U/ml. A plaque reduction assay of this
final wash showed no inhibitory activity. The cultures were
infected immediately after the washing procedure, and the
incorporation of [3H]uracil was measured 2 days later.
Although the interferon in the medium was removed by
washing, 1 day of interferon treatment was still sufficient to
establish resistance to T. gondii (Table 3).
TABLE 3. Inhibition of the growth of T. gondii when the
interferon was added 24 h before infection
% of control [3H]uracil incorporation 24 h after
infectiona
Interferon
(U/ml) Interferon washed Interferon present
out at the time of throughoutinfection
128 23 ± 2b 16 ± 2
64 23 ± 2 15 ± 3
32 40±1 20±1
16 117 ± 18 27 ± 3
8 107 ± 18 104 ± 6
a The control incorporation in the absence of interferon was 6.4 x
104 cpm per culture.
b Mean and standard deviation of quadruplicate samples.
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Before we considered the mechanism by which gamma
interferon blocks the growth of T. gondii, it was first
necessary to exclude the possibility of a direct parasiticidal
effect on extracellular parasites. To examine this possibility,
we released the parasites from their host cells and incubated
107 parasites per ml at 37°C in fresh medium that contained
128 U of interferon per ml or no interferon. Viable parasites
were assayed at intervals by plaque formation, with dilutions
that reduced the interferon concentration well below the
MIC. Both the interferon-treated and control extracellular
parasites died at roughly the same rate (Fig. 3).
Since a host cell is essential for the growth of T. gondii, we
considered the possibility that the interferon so severely
affected the host cell that the growth of the parasites was
compromised. A series of replicate human fibroblast cul-
tures were treated with 32 U of gamma interferon per ml,
whereas others received control medium. At daily intervals
we measured macromolecular synthesis in these uninfected
cultures by the incorporation of labeled uridine, thymidine,
and leucine. RNA and DNA synthesis showed a slight initial
increase followed by a decline (Fig. 4). Protein synthesis
declined progressively. These data show the most dramatic
effect of gamma interferon on the host cells that was
observed. Other experiments showed no significant inhibi-
tion of the incorporation of thymidine. As argued below,
N,
0
N.
a-
E
10
2 4 6 8
Hours at 37C.
FIG. 3. Comparison of the viability of extracellular T. gondii
incubated in the presence (0) or absence (0) of 128 U of gamma
interferon per ml. The incubation was done at 37°C in medium that
contained 3% serum. Samples were removed at intervals to measure
the PFU titer at dilutions that precluded any action of residual
interferon.
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FIG. 4. Effect of 32 U of gamma interferon per ml on the
incorporation of [3H]leucine (A), [3H]thymidine (0), and [3H]uri-
dine (0) into acid-precipitable material by uninfected fibroblasts.
Quadruplicate control and interferon-treated cultures were labeled
in 4-h pulses with 5 pCi/ml. The data from the interferon-treated
cultures are plotted as a percentage of the control value for each
time.
even the greatest observed effects on macromolecule synthe-
sis by the host cells are unlikely to block the growth of the
parasite.
We also examined the antitoxoplasma effect of human
recombinant alpha and beta interferons by both the [3HJura-
cil incorporation assay and the plaque reduction test. Nei-
ther of these interferons had any effect at 1,024 U/ml, the
highest concentration tested (data not shown). In our human
fibroblasts, both of these interferons inhibited vesicular
stomatitis virus at a concentration of 2 U/ml. As noted
below, these observations excluded some mechanisms for
the antitoxoplasma activity of gamma interferon.
DISCUSSION
The human recombinant gamma interferon used in these
studies differs in at least one significant way from the natural
substance. The recombinant gamma interferon, like all bac-
terial proteins, is unglycosylated. Despite this difference, the
recombinant gamma interferon had a high antiviral activity
in the titration carried out at Genentech, Inc., with vesicular
stomatitis virus and HeLa cells. Recombinant gamma inter-
feron also inhibited the growth of T. gondii in cultured
fibroblasts. This observation proves that at least some of the
antitoxoplasma activity observed by others in crude lympho-
kines can be ascribed to gamma interferon. It supports the
tentative conclusion of Shirahata and Shimizu (20) that a
murine lymphokine that blocked the growth of T. gondii in
mouse L-cells was gamma interferon. Their conclusion was
based on several properties of the lymphokine, including
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molecular weight, lability at pH 2, and susceptibility only to
proteolytic enzymes. Our observations are also consistent
with the conclusion that the antitoxoplasma lymphokine was
not interleukin-2 (3). However, gamma interferon is clearly
distinct from a hamster antiparasitic lymphokine described
by Chinchilla and Frenkel (5). These authors found that their
active material had a much lower molecular weight of 4,000
to 5,000 and specifically protected hamster kidney cells only
against the parasite (T. gondii or Besnoitiajellisoni) that was
used to sensitize the lymphocytes. There is no evidence that
interferon has such specificity for infectious agents and,
indeed, recombinant gamma interferon protected almost
equally well against T. gondii and vesicular stomatitis virus.
There is reason to believe that the gamma interferon restrict-
ed the growth of T. gondii by a direct cytotoxic effect on the
human fibroblast host cells. All interferons have an antipro-
liferative effect on their homologous cells. Some evidence of
this can be seen in our measurements of DNA, RNA, and
protein synthesis in human fibroblasts treated with gamma
interferon (Fig. 4). Although the cells showed no cytopathic
effect by phase-contrast microscopy, 3 days after treatment
the synthesis of each of these macromolecules was reduced
to 50 to 60% of normal. This reduced rate of synthesis is
unlikely to compromise the growth of T. gondii. It is known
that the parasite does not require host protein synthesis (16)
and that enucleated cells, which can only have mitochondrial
RNA and DNA synthesis, support the growth of T. gondii
(10, 19). We can also exclude a direct effect of gamma
interferon on extracellular T. gonidii. Although free parasites
die rapidly in our medium, there was no increase in the rate
of death in the presence of gamma interferon (Fig. 3). An
effect on extracellular parasites is also excluded by the
experiment in which host cells restricted the growth of the
parasite even though the gamma interferon had been re-
moved by washing the monolayer before infection (Table 3).
The inhibition of T. gondii by human recombinant gamma
interferon shares some features with the antiviral activity of
interferon (11). We found that the antitoxoplasma state was
not established immediately upon contact with interferon
but, rather, required some time to develop. Once the inhibi-
tory state was developed, however, it was no longer neces-
sary for the interferon to remain in the medium. All interfer-
ons are thought to exert their antiviral effect by binding to
specific receptors and then inducing the synthesis of new
proteins. Thus, the establishment of the antiviral state can be
blocked by inhibiting host cellular protein or RNA synthesis.
Two of the proteins induced by all three interferons have
been implicated in their antiviral activity (reviewed in refer-
ence 11). One is a protein kinase that phosphorylates and
hence inactivates the elongation factor eIF2. The other is an
enzyme that synthesizes the polynucleotide 2-SA that then
serves to activate an endonuclease that attacks RNA. Both
of these interferon-induced enzymes are activated by dou-
ble-stranded RNA that is thought to be a by-product of viral
replication. Thus, protein synthesis is compromised in a cell
that was pretreated with interferon and then infected with a
virus.
The antiviral mechanisms thought to be shared by all three
kinds of interferon are quite unlikely to account for the
antitoxoplasma activity of gamma interferon. The growing
intracellular parasite is separated from the cytoplasm of its
host cell by two membranes, the membrane of the parasite
itself and that of its parasitophorous vacuole. It would not be
expected that the interferon-induced enzymes that exert the
antiviral effect could cross these membranes. Similarly,
these barriers should be impermeable to the effector mole-
cule 2-5A. The conclusion that the antitoxoplasma activity
induced by gamma interferon cannot be mediated by the
same biochemical mechanisms that inhibit viral growth is
strongly supported by our demonstration that human recom-
binant alpha and beta interferons had no effect on the growth
of T. gondii, although they are presumed to induce the same
antiviral proteins as gamma interferon.
It is likely that some additional protein(s) induced by
gamma interferon is responsible for its antitoxoplasma ef-
fect. In this context, it is of interest that recent reports have
shown that gamma interferon induced the synthesis of at
least three mRNAs (6) and six proteins (22) in addition to
those that were also induced by alpha or beta interferons.
One or more of these host cell proteins peculiar to gamma
interferon treatment may be responsible for the antitoxo-
plasma effect. The observed suppression of host cell RNA
and protein synthesis by gamma interferon (Fig. 4) need not
compromise the synthesis of putative proteins that inhibit
the growth of T. gondii. We have shown that the antiparasite
state was largely established during day 1 of treatment with
gamma interferon (Tables 2 and 3), a period during which the
synthesis of host cell macromolecules was not affected.
During the subsequent days, proteins induced by gamma
interferon could be preferentially synthesized even in the
face of some inhibition of total RNA and protein synthesis.
We have suggested an antiparasitic mechanism in which
gamma interferon induces an enzyme(s) that degrades tryp-
tophan (E. R. Pfefferkorn, submitted for publication).
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